Product details
Background：Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
• SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin., PMID:28424516
• 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer., PMID:30347240
• CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma., PMID:23731618
• CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes., PMID:17878365
• The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders., PMID:40073958
• Hematologic Malignancies: Plasma Cell Disorders., PMID:28561703
• Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma., PMID:28356715
• 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes., PMID:11513145
• Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma., PMID:39060023
• Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma., PMID:27533882
